Introduction

Successful milestones achieved and upcoming include peer-reviewed publications, commercial agreements, and payer coverage decisions.

Addressing Chronic Low Back Pain

Progressing with proven path toward standard of care addressing chronic low back pain, the largest expenditure in US healthcare costing Americans an estimated $134 Billion annually.

Investment in AI Technology

More than $50 Million has been invested in the promising Aclarion AI platform that aids physicians in identification of painful discs.

Intellectual Property Protection

Technology protected by 23 issued US patents, 17 issued international patents, and 12 pending patent applications.

Payer Coverage Expansion

Three of four largest private insurance payers in the UK now covering Nociscan.

Strategic Partnerships

Partnership with ten prominent KOL surgeons signed on to assist Aclarion in successfully gaining traction and reimbursement throughout the United States.

CEO’s Perspective

“We are excited with the recent positive success we have been awarded as Aclarion has consistently achieved stated catalysts of value creation,” said Brent Ness, CEO of Aclarion. “Payer coverage is critical to driving Nociscan to standard of care.”

Key Opinion Leaders (KOLs)

The cornerstone of Aclarion’s strategy to drive payer coverage is to partner with Key Opinion Leader (KOL) physicians who see the value of Nociscan in their practice.

Success in the UK

Aclarion’s KOL advocacy strategy applied to the UK has led to great success, with three of the top four payers agreeing to pay for Nociscan.

Expansion into the US Market

By partnering with Justin Kubeck, MD, Aclarion is expanding into the personal injury and workers compensation market.

Clinical Trials and Evidence

Evidence continues to mount in favor of utilizing Nociscan to determine discogenic pain over the current invasive gold standard.

Future Outlook

In the months ahead, investors can rely on continued success in adding peer-reviewed evidence publications, signing additional commercial agreements, and expanding positive payer coverage decisions.

For More Information

For more information about the BEST Trial, please visit: www.besttrial.org

For information about BACPAC, please visit: https://heal.nih.gov/research/clinical-research/back-pain

For more information about REACH, please visit: www.bacpac-reach.org